Standard Biotools LAB
NASDAQ LAB
$0.65 -0.02 (-3.63%)
At close: Aug 20, 2026 · 2:55 PM UTC

Standard Biotools (LAB) Preferred Stock Liabilities (2022 - 2023)

Standard Biotools (LAB) posted quarterly Preferred Stock Liabilities of $311.3 million for Q4 2023, little changed year-over-year from $311.3 million in Q4 2022, and little changed quarter-over-quarter from $311.3 million in Q3 2023.

Standard Biotools (LAB) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends

Standard Biotools (LAB) has reported Preferred Stock Liabilities for 2 consecutive years, with $311.3 million the latest figure, recorded in Q4 2023.

  • In Q4 2023, Preferred Stock Liabilities changed 0.0% year-over-year to $311.3 million; the TTM figure through Dec 2023 stood at $311.3 million (changed 0.0% YoY), while the FY2023 annual figure was $311.3 million, changed 0.0% from the prior year.
  • Preferred Stock Liabilities was little changed at $311.3 million in Q4 2023 per LAB's latest filing, from $311.3 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $311.3 million in Q2 2022 and bottomed at $311.3 million in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Abbott Laboratories 199.75 Bn 194.14 Bn 7.27 Bn -
2 Stryker 127.36 Bn 123.88 Bn 4.50 Bn -
3 Medtronic 118.98 Bn 109.76 Bn 6.41 Bn -
4 Boston Scientific 73.20 Bn 72.66 Bn 3.85 Bn -
5 Edwards Lifesciences 52.10 Bn 47.85 Bn 1.35 Bn -
6 Dexcom 34.32 Bn 32.37 Bn 830.00 Mn -
7 GE HealthCare Technologies 33.77 Bn 31.66 Bn 2.18 Bn -
8 Koninklijke Philips 26.36 Bn 23.04 Bn 4.55 Bn -
9 Steris 23.04 Bn 22.56 Bn 684.20 Mn -
10 Standard Biotools 252.98 Mn -223.74 Mn 10.54 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 311.25 Mn
Sep 30, 2023 311.25 Mn
Jun 30, 2023 311.25 Mn
Mar 31, 2023 311.25 Mn
Dec 31, 2022 311.25 Mn
Sep 30, 2022 311.25 Mn
Jun 30, 2022 311.25 Mn